Further support for the importance of tight PI3K signal regulation in Tregs comes from studies with selective PI3K inhibitors like the p110δ inhibitor idelalisib, which demonstrated preferential effects on Tregs in chronic lymphocytic leukemia (CLL) patients40. This evidence concerns the gene PIK3CD and B-cell chronic lymphocytic leukemia.